🚀 RECENT AI SUCCESS

Our AI successfully predicted the gap for $PLAY and executed a BUY strategy, securing a +29.52% net profit.

UPGRADE TO SEE LIVE SIGNALS

$ARVN

Arvinas Inc.

United StatesUNITED STATES
FREE PREVIEW
AVG HISTORICAL GAP0.00%
MAX GAP RECORD0.00%
PREMIUM
AI ACCURACY RATE
92.4%
Unlock AI Insights 🔓

LAST 10 EARNINGS GAPS (%)

VOLATILITY & BIAS PROFILE

AVG VOLATILITY0.0%
Bullish Gaps
Bearish Gaps
Neutral

Intelligence Brief

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC… Read full dossier

CURRENT AI SIGNAL
BULLISH STRONG
🔓 REVEAL SIGNAL